Lipid formulations of amphotericin B: Recent progress and future directions

Clinical Infectious Diseases

Volumn 22, Issue SUPPL. 2, 1996, Pages

  Hiemenz, John W ^a   Walsh, Thomas J ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; DIMYRISTOYLPHOSPHATIDYLCHOLINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CLINICAL TRIAL; COLLOID; CONFERENCE PAPER; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID ABSORPTION; MEMBRANE BINDING; META ANALYSIS; MOUSE; MYCOSIS; NONHUMAN; PHARMACEUTICS; PRIORITY JOURNAL; RAT; RETICULOENDOTHELIAL SYSTEM;

EID: 0030016915     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.supplement_2.s133     Document Type: Conference Paper

References (83)

1. Bodey GP. The emergence of fungi as major hospital pathogens. J Hosp Infect 1988;11(suppl A):411-26.
2. Walsh TJ, Pizzo PA. Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation. Annu Rev Microbiol 1988;42:517-45.
3. Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988;157:624-8.
4. Beck Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993;167:1247-51.
5. Weiland D, Ferguson RM, Peterson PK, Snover DC, Simmons RL, Najarian JS. Aspergillosis in 25 renal transplant patients: epidemiology, clinical presentation, diagnosis, and management. Ann Surg 1983; 198:622-9.
6. Tollemar J, Ericzon BG, Holmberg K, Andersson J. The incidence and diagnosis of invasive fungal infections in liver transplant recipients. Transplant Proc 1990;22:242-4.
7. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992;14(suppl 1):S43-53.
8. Meyers JD. Fungal infections in bone marrow transplant patients. Semin Oncol 1990;17(suppl 6):10-3.
9. DeBock R. Epidemiology of invasive fungal infections in bone marrow transplantation. Bone Marrow Transplant 1994;14(suppl 5):S1-2.
10. Wingard JR, Beals SU, Santos GW, Merz WG, Saral R. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant 1987;2:175-81.
11. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11:379-90.
12. Walsh TJ, Dixon DM. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis, and treatment. Eur J Epidemiol 1989;5:131-42.
13. Anaissie E, Bodey GP, Kantarjian H, et al. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989;11:369-78.
14. Anaissie E, Kantarjian H, Ro J, et al. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) 1988;67: 77-83.
15. Walsh TJ. Management of immunocompromised patients with evidence of an invasive mycosis. Hematol Oncol Clin North Am 1993;7: 1003-26.
16. Sarosi GA. Amphotericin B: still the 'gold standard' for antifungal therapy. Postgrad Med 1990;88:151-2, 155-61, 165-6.
17. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990;12:308-29.
18. Walsh TJ, Pizzo PA. Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis 1988;7: 460-75.
19. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive fungal aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990;12:1147-201.
20. Bangham AD. Liposomes: realizing their promise. Hosp Pract Off Ed 1992;27:51-6, 61-2.
21. Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 1989;46:1576-87.
22. New RR, Chance ML, Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother 1981;8:371-81.
23. Graybill JR, Craven PC, Taylor RL, Williams DM, Magee WE. Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis 1982;145:748-52.
24. Taylor RL, Williams DM, Craven PC, Graybill JR, Drutz DJ, Magee WE. Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis 1982;125:610-1.
25. Lopez-Berestein G, Hopfer RL, Mehta R, Mehta K, Hersh EM, Juliano RL. Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. J Infect Dis 1984;150:278-83.
26. Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 1985;151:704-10.
27. Lopez-Berestein G, Bodey GP, Frankel LS, Mehta K. Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol 1987;5:310-7.
28. Janoff AS, Boni LT, Popescu MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988;85:6122-6.
29. Janoff AS, Perkins WR, Saleton SL, Swenson CE. Amphotericin B lipid complex (ABLC™): a molecular rationale for the attenuation of amphotericin B-related toxicities. Journal of Liposome Research 1993;3: 451-72.
30. Wasan KM, Lopez-Berestein G. The interaction of liposomal amphotericin B and serum lipoproteins within the biological milieu. Journal of Drug Targeting 1994;2:373-80.
31. Clark JM, Whitney RR, Olsen SJ, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991;35:615-21.
32. Olsen SJ, Swerdel MR, Blue B, Clark JM, Bonner DP. Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol 1991;43:831-5.
33. Lee J, Allende M, Dollenberg H, et al. Reticuloendothelial loading with amphotericin B lipid complex (ABLC) - a novel pharmacodynamic approach to treatment of experimental hepatosplenic candidiasis (HSC). [abstract no 172]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (Anaheim). Washington, DC: American Society for Microbiology, 1992:139.
34. Whitney RR, Kunselman L, Clark JM, Bonner DP. Efficacy of amphotericin B lipid complex (ABLC) in cryptococcal meningitis in normal or immunocompromised mice [abstract no 166]. In: Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy (Houston). Washington, DC: American Society for Microbiology. 1989:128.
35. Clemons KV, Stevens DA. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob Agents Chemother 1991;35:2144-6.
36. Perfect JR, Wright KA. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother 1994;33:73-81.
37. Kan VL, Bennett JE, Amantea MA, et al. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J Infect Dis 1991;164:418-21.
38. Llanos-Cuentas A, Cieza J, Echevarria J, et al. The safety and tolerance of amphotericin B lipid complex (ABLC) vs. amphotericin B desoxycholate (Fungizone, [AB]) in patients with mucocutaneous leishmaniasis (MCL) [abstract no 234]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (Anaheim). Washington, DC: American Society for Microbiology, 1992:149.
39. Sharkey PK, Lipke R, Renteria A, et al. Amphotericin B lipid complex (ABLC) in treatment (Rx) of coccidioidomycosis (C) [abstract no 742] In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 1991:222.
40. Graybill JR, Sharkey PK, Vincent D, et al. Amphotericin B lipid complex (ABLC) in treatment (Rx) of cryptococcal meningitis (CM) in patients with AIDS [abstract no 289]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 1991:147.
41. Anaissie EJ, White M, Uzun O, et al. Amphotericin B lipid complex (ABLC®) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial [abstract no. LM 21]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:330.
42. Walsh TJ, Hiemenz JW, Seibel N, Anassie EJ. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis [abstract no M69]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando). Washington, DC: American Society for Microbiology, 1994:247.
43. Hiemenz JW, Lister J, Anaissie EJ, et al. Emergency-use amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical control comparison with amphotericin B [abstract no 3383]. Blood 1995;86(suppl 1):849a.
44. Guo LSS, Fielding RM, Lasic DD, et al. Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. International Journal of Pharmaceutics 1991;75:45-54.
45. Hanson LH, Stevens DA. Comparison of antifungal activity of amphotericin B desoxycholate with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob Agents Chemother 1992;36:486-8.
46. Fielding RM, Smith PC, Wang LH, Porter J, Guo LS. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 1991;35:1208-13.
47. Fielding RM, Singer AW, Wang LH, Babbar S, Guo LS. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother 1992;36:299-307.
48. Fielding RM, Porter J, Jekot J, Guo LSS. Altered tissue distribution results in the reduced toxicity of amphotericin B colloidal dispersion [abstract no A77]. In: Proceedings of the 91st annual meeting of the American Society for Microbiology (Dallas). Washington, DC: American Society for Microbiology, 1991:13.
49. Clemons KV, Stevens DA. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother 1991;35:1829-33.
50. Hostetler JS, Clemons KV, Hanson LH, Stevens DA. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B desoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob Agents Chemother 1992;36:2656-60.
51. Patterson TF, Miniter P, Dijkstra J, Szoka FC Jr, Ryan JL, Andriole VT. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis 1989;159:717-24.
52. Allende MC, Lee JW, Francis P, et al. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1994; 38:518-22.
53. Walsh TJ, Garrett K, Feverstein E, et al. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography: a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother 1995;39:1065-9.
54. Hostetler JS, Caldwell JW, Johnson RH, et al. Coccidioidal infections treated with amphotericin B colloidal dispersion (Amphocil or ABCD) [abstract no 628]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (Anaheim). Washington, DC: American Society for Microbiology, 1992:215.
55. Bowden RA, Cays M. Phase I study of amphotericin B colloidal dispersion (ABCD: Amphocil) for the treatment of invasive fungal infection after marrow transplant [abstract no 1685]. Blood 1993;82(suppl 1):425a.
56. Oppenheim BA, Herbrecht R, Kusne S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 1995;21:1145-53.
57. Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. Journal of Liposome Research 1993;3:429-50.
58. Anaissie E, Paetznick V, Proffitt R, Adler-Moore J, Bodey GP. Comparison of the in vitro antifungal activity of free and liposomal-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis 1991;10:665-8.
59. Pahls S, Schaffner A. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J Infect Dis 1994;169:1057-61.
60. Proffitt RT, Satorius A, Chiang SM, Sullivan L, Adler-Moore JP. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 1991;28(suppl B): 49-61.
61. Lee JW, Amantea MA, Francis PA, et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 1994;38:713-8.
62. Gondal JA, Swartz RP, Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother 1989;33:1544-8.
63. Francis P, Lee JW, Hoffman A, et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis 1994;169:356-68.
64. Tollemar J, Ringden O. Early pharmacokinetic and clinical results from a noncomparative multicenter trial of amphotericin B encapsulated in a small unilamellar liposome (AmBisome) in rodents. Drug Investigation 1992;4:232-8.
65. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28(suppl B):73-82.
66. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome):safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991;28(suppl B):83-91.
67. Walsh TJ, Bekersky I, Yeldandi V, et al. Pharmacokinetics of AmBisome in persistently febrile neutropenic patients receiving empirical antifungal therapy [abstract no A11]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:13.
68. Atkinson AJ Jr, Bennett JE. Amphotericin B pharmocokinetics in humans. Antimicrob Agents Chemother 1978;13:271-6.
69. Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother 1989;33:1989-93.
70. Sanders SW, Buchi KN, Goddard MS, Lang JK, Tolman KG. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob Agents Chemother 1991;35:1029-34.
71. Walsh TJ, Whitcomb T, Hill S, Pizzo PA. Safety, tolerance, pharmacokinetics, and efficacy of amphotericin lipid complex (ABLC) in the treatment of hepatosplenic candidiasis in children. In: Proceedings of the Conference on Candida and Candidiasis: Biology, Pathogenesis, and Management. Washington, DC: American Society for Microbiology, 1996 (in press).
72. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994;86:754-60.
73. Ng TTC, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch Intern Med 1995;155:1093-8.
74. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993;12:577-82.
75. Ringden O. Clinical experience with AmBisome with special emphasis on experience with children. Bone Marrow Transplant 1993;12(suppl 4):S149-50.
76. Tollemar J, Duraj F, Ericzon BG. Liposomal amphotericin B treatment in a 9-month-old liver recipient. Mycoses 1990;33:251-2.
77. Lackner H, Schwinger W, Urban C, et al. Liposomal amphotericin-B (AmBisome) for treatment of disseminated fungal infections in two infants of very low birth weight. Pediatrics 1992;89:1259-61.
78. Kirsh R, Goldstein R, Tarloff J, et al. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 1988;158:1065-70.
79. Chavanet PY, Garry I, Charlier N, et al. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ 1992;305:921-5.
80. Caillot D, Casasnovas O, Solary E, et al. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 1993;31:161-9.
81. Moreau P, Milpied N, Fayette N, Ramee JF, Harousseau JL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 1992;30:535-41.
82. Trissel LA. Amphotericin B does not mix with fat emulsion [letter]. Am J Health Syst Pharm 1995;52:1463-4.
83. Persson U, Tennvall GR, Andersson S, et al. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycosis. PharmacoEconomics 1992;2:500-8.